logo
Science Portal
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
About MSF Science Portal
About
Contact Us
Frequently Asked Questions (FAQs)
Privacy Policy
Terms of Use
Copyright © Médecins Sans Frontières
v2.1.5153.produseast1
Showing 1 - 6 of 6 Items
Showing 1 - 6 of 6 Items
Sort By: Relevance
  • Newest to oldest
  • Oldest to newest
  • Relevance
Journal Article
|
Research

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A,  et al.
2025-01-29 • New England Journal of Medicine
2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article
|
Research

The frequency and incidence of QT prolongation with extended use of bedaquiline or delamanid in a large, multi-country MDR/RR-TB cohort

Khan U, Rich M, Franke M, Lachenal N, Ahmed S,  et al.
2024-12-10 • Clinical Infectious Diseases
2024-12-10 • Clinical Infectious Diseases

BACKGROUND

The 2022 WHO guidelines on multi-drug/rifampicin resistant tuberculosis (MDR/RR-TB) recommend six months of bedaquiline (Bdq) in the all-oral 9-month shorter regimen ...

Journal Article
|
Research

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A,  et al.
2024-01-29 • medRxiv
2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article
|
Letter

Eligibility for the shorter multidrug-resistant tuberculosis regimen: ambiguities in the World Health Organization recommendations

Varaine FFV, Guglielmetti L, Huerga H, Bonnet MMB, Kiria N,  et al.
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
2016-10-15 • American Journal of Respiratory and Critical Care Medicine
Journal Article
|
Research

Is 6 months of bedaquiline enough? Results from the compassionate use of bedaquiline in Armenia and Georgia

Hewison CCH, Bastard M, Khachatryan N, Kotrikadze T, Hayrapetyan A,  et al.
2018-07-01 • International Journal of Tuberculosis and Lung Disease
2018-07-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND AND SETTING
Bedaquiline (BDQ) was initially only available through compassionate use programmes.

OBJECTIVE
To assess the effectiveness and safety of multidrug...
Journal Article
|
Research

Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries

Guglielmetti L, Hewison CCH, Avaliani Z, Hughes AJ, Kiria N,  et al.
2017-02-01 • International Journal of Tuberculosis and Lung Disease
2017-02-01 • International Journal of Tuberculosis and Lung Disease
BACKGROUND
For the first time in almost 50 years, there are new drugs available for the treatment of tuberculosis (TB), including bedaquiline (BDQ) and delamanid (DLM). The rate of i...